Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017

SAN FRANCISCO, Nov. 7, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2017.

Cash and investments in marketable securities at September 30, 2017 were $412.2 million as compared to $389.1 million at December 31, 2016. The cash balance includes the $150.0 million upfront payment from Nektar’s collaboration with Eli Lilly & Company for the development and commercialization of NKTR-358.

“Nektar’s immuno-oncology portfolio continues to expand as we add novel drug candidates to our growing pipeline,” said Howard W. Robin, President and CEO of Nektar. “NKTR-214 is the first I-O agent to both increase tumor-infiltrating lymphocytes (TILs) and increase PD-1 expression on human immune cells, which uniquely complements checkpoint inhibition and other anti-cancer mechanisms. As the majority of cancer patients have tumors that do not express PD-L1 and these patients receive limited benefit from treatment with checkpoint inhibitors, the potential of NKTR-214 to help patients is significant. Finally, based on recent positive conversations with the agency regarding our regulatory plans for NKTR-181, we are now planning to submit an NDA for NKTR-181 by April 2018 with our data package of over 2,100 patients and healthy volunteers.”

Revenue in the third quarter of 2017 was $152.9 million as compared to $36.3 million in the third quarter of 2016. Year-to-date revenue for 2017 was $212.2 million as compared to $128.0 million in the first nine months of 2016. Revenue in 2017 included recognition of $127.6 million of the $150.0 million upfront payment from Nektar’s collaboration with Eli Lilly & Company for the development and commercialization of NKTR-358.

Total operating costs and expenses in the third quarter of 2017 were $83.4 million as compared to $69.2 million in the third quarter of 2016. Year-to-date total operating costs and expenses in 2017 were $247.9 million as compared to $208.7 million for the same period in 2016. Total operating costs and expenses increased primarily as a result of increased research and development (R&D) expense.

Research and development expense in the third quarter of 2017 was $65.7 million as compared to $52.0 million in the third quarter of 2016. Year-to-date R&D expense for 2017 was $187.0 million as compared to $153.6 million for the same period in 2016. R&D expense was higher in the third quarter and first nine months of 2017 as compared to the same periods in 2016 primarily because of expenses for our pipeline programs, including Phase 3 clinical studies for NKTR-181, Phase 1/2 clinical studies of NKTR-214 and NKTR-358 and IND-enabling activities for NKTR-262 and NKTR-255.

General and administrative expense was $12.1 million in the third quarter of 2017 as compared to $10.3 million in the third quarter of 2016. G&A expense in the first nine months of 2017 was $40.0 million as compared to $31.5 million for the same period in 2016. G&A expense in the first nine months of 2017 includes a $3.3 million charge for a litigation settlement related to a cross-license agreement.

Net income in the third quarter of 2017 was $60.9 million or $0.39 basic income per share as compared to net loss of $43.2 million or $0.32 basic loss per share in the third quarter of 2016. Net loss in the first nine months of 2017 was $62.9 million or $0.41 basic loss per share as compared to $111.3 million or $0.82 basic loss per share in the first nine months of 2016.

The company also announced upcoming presentations at the following scientific congresses during the fourth quarter of 2017:

Society for Immunotherapy in Cancer (SITC) 32^nd Annual Meeting, National Harbor, MD:

Oral Presentation: “PIVOT-02: Preliminary safety, efficacy and biomarker results from the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic solid tumors”
Presenter: Dr. Adi Diab, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Session: Clinical Trials: Novel Combinations
Date: Saturday, November 11, 2017, 5:00 p.m. Eastern Time

Poster #P77: “The Novel IL-2 Cytokine Immune Agonist NKTR-214 Harnesses the Adaptive and Innate Immune System for the Treatment of Solid Cancers”
Presenter: Salah Eddine Bentebibel, University of Texas MD Anderson Cancer Center
Session: Biomarkers and Immune Monitoring
Date: Friday, November 10, 2017, 12:30-2:00 p.m. Eastern Time

Poster #P140: “NKTR-214 enhances anti-tumor T-cell immune responses induced by checkpoint blockade or vaccination”
Presenter: Meenu Sharma, University of Texas MD Anderson Cancer Center
Session: Cancer Vaccines
Date: Saturday, November 11, 2017, 12:30-2:00 p.m. Eastern Time

Poster #P274: “Combination of NKTR-214 and radiotherapy (RT) to reverse anergy and expand tumor-specific CD8 T-Cells”
Presenter: Joshua Walker, Oregon Health & Science University
Session: Combination Therapy
Date: Saturday, November 11, 2017, 12:30-2:00 p.m. Eastern Time

Poster #P275: “Harnessing the innate and adaptive immune system to eradicate treated and distant untreated solid tumors”
Presenter: Saul Kivimae, Nektar Therapeutics
Session: Combination Therapy
Date: Friday, November 10, 2017, 12:30-2:00 p.m. Eastern Time

Poster #P332: “Pre-clinical efficacy and tolerability of NKTR-255, a polymer-conjugated IL-15 for immuno-oncology”
Presenter: Peiwen Kuo, Nektar Therapeutics
Session: Combination Therapy
Date: Saturday, November 11, 2017, 12:30-2:00 p.m. Eastern Time

Poster #434: “Great Apes Adenoviral vaccine encoding neoantigens synergizes with immunomodulators to cure established tumors in mice”
Presenter: Anna Morena D’Alise, Nouscom srl
Session: Personalized Vaccines and Technologies/Personalized Medicines
Date: Saturday, November 11, 2017, 12:30-2:00 p.m. Eastern Time

American College of Neuropsychopharmacology 56^th Annual Meeting, Palm Springs, CA:

Poster #T166: “Abuse potential of NKTR-181 in recreational opioid users: results from a randomized, double-blind crossover oral study”
Presenter: Snow Ge, Nektar Therapeutics
Session: Poster Session II
Date: Tuesday, December 5, 2017, 5:30-7:30 p.m. Pacific Time

Conference Call to Discuss Third Quarter 2017 Financial Results
Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, Tuesday, November 7, 2017.

This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: http://ir.nektar.com/index.cfm. The web broadcast of the conference call will be available for replay through Monday, December 11, 2017.

To access the conference call, follow these instructions:
Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)
Passcode: 4677348 (Nektar Therapeutics is the host)

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar’s proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains uncertain or forward-looking statements which can be identified by words such as: “could,” “plan,” “expect,” “should,” “may,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential therapeutic benefits of and future development plans for our products (including NKTR-181, NKTR-358, NKTR-214, NKTR-262 and NKTR-255), the potential impact of NKTR-181 with respect to the opioid abuse epidemic, the timing and strategy for regulatory filings (including the timing and strategy for filing a new drug application, “NDA”) and meetings with representatives of the Food and Drug Administration (FDA) and other governmental officials, and the results of clinical trials. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements and you should not rely on such statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include: (i) clinical study outcomes remain very unpredictable and it is possible that a clinical study could fail even after positive interim data is observed; (ii) the regulatory pathway to review and approve pharmaceutical products is subject to substantial uncertainty; (iii) the data package required for filing and approval of an NDA to the FDA is very uncertain and difficult to predict due to broad FDA regulatory discretion, established guidance and precedent (e.g., the practice of typically requiring two placebo-controlled pivotal studies to support NDA approvals for drugs like NKTR-181), and changing FDA regulatory guidelines; (iv) the final outcomes and conclusions from sponsor meetings with FDA are subject to substantial FDA discretion associated with issuing final meeting minutes and outcomes; (v) regulations concerning and controlling access to opioid-based pharmaceuticals are strict and is difficult to predict which scheduling category will apply to NKTR-181 if regulatory approval is achieved; (vi) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2017. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement.

Contact:
For Investors:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Jodi Sievers of Nektar Therapeutics
415-482-5593

 NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) ASSETS September 30, 2017 December 31, 2016 (1) ------------------ ----------------- Current assets: Cash and cash equivalents $37,967 $59,640 Short-term investments 314,600 329,462 Accounts receivable, net 3,314 15,678 Inventory 13,654 11,109 Other current assets 13,260 10,063 Total current assets 382,795 425,952 Long-term investments 59,596 - Property, plant and equipment, net 62,396 65,601 Goodwill 76,501 76,501 Other assets 767 817 --- --- Total assets $582,055 $568,871 ======== ======== LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $8,563 $2,816 Accrued compensation 19,088 18,280 Accrued clinical trial expenses 7,000 7,958 Other accrued expenses 9,302 4,711 Interest payable 4,198 4,198 Capital lease obligations, current portion 2,482 2,908 Liability related to refundable upfront payment 12,500 12,500 Deferred revenue, current portion 25,491 14,352 Other current liabilities 3,920 4,499 Total current liabilities 92,544 72,222 Senior secured notes, net 244,771 243,464 Liability related to the sale of future royalties, net 98,394 105,950 Deferred revenue, less current portion 56,225 51,887 Other long-term liabilities 5,959 7,223 ----- ----- Total liabilities 497,893 480,746 Commitments and contingencies Stockholders’ equity: Preferred stock - - Common stock 15 15 Capital in excess of par value 2,170,169 2,111,483 Accumulated other comprehensive loss (1,907) (2,363) Accumulated deficit (2,084,115) (2,021,010) Total stockholders’ equity 84,162 88,125 Total liabilities and stockholders’ equity $582,055 $568,871 

 (1) The consolidated balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. 

 NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share information) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, -------------------------------- --------------------------- 2017 2016 2017 2016 ---- ---- ---- ---- Revenue: Product sales $4,448 $14,698 $24,897 $41,664 Royalty revenue 9,302 5,573 23,953 13,150 Non-cash royalty revenue related to sale of future royalties 8,066 7,692 21,367 22,341 License, collaboration and other revenue 131,112 8,373 142,028 50,829 Total revenue 152,928 36,336 212,245 127,984 Operating costs and expenses: Cost of goods sold 5,674 7,033 20,794 23,611 Research and development 65,714 51,951 187,032 153,569 General and administrative 12,055 10,253 40,027 31,515 Total operating costs and expenses 83,443 69,237 247,853 208,695 ------ ------ ------- ------- Income (loss) from operations 69,485 (32,901) (35,608) (80,711) Non-operating income (expense): Interest expense (5,540) (5,614) (16,452) (16,918) Non-cash interest expense on liability related to sale of future royalties (4,471) (4,902) (13,535) (14,929) Interest income and other income (expense), net 1,599 332 3,163 1,666 Total non-operating expense, net (8,412) (10,184) (26,824) (30,181) Income (loss) before provision for income taxes 61,073 (43,085) (62,432) (110,892) Provision for income taxes 202 139 434 433 --- --- --- --- Net income (loss) $60,871 $(43,224) $(62,866) $(111,325) ======= ======== ======== ========= Net income (loss) per share: Basic $0.39 $(0.32) $(0.41) $(0.82) Diluted $0.37 $(0.32) $(0.41) $(0.82) Weighted average shares outstanding used in computing net income (loss) per share: Basic 156,411 137,094 155,153 136,415 Diluted 162,641 137,094 155,153 136,415 

 NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Nine Months Ended September 30, ------------------------------- 2017 2016 ---- ---- Cash flows from operating activities: Net loss $(62,866) $(111,325) Adjustments to reconcile net loss to net cash used in operating activities: Non-cash royalty revenue related to sale of future royalties (21,367) (22,341) Non-cash interest expense on liability related to sale of future royalties 13,535 14,929 Stock-based compensation 25,118 18,793 Depreciation and amortization 12,081 11,502 Other non-cash transactions (1,370) (2,190) Changes in operating assets and liabilities: Accounts receivable, net 12,364 5,698 Inventory (2,545) 592 Other assets (2,036) 6,041 Accounts payable 5,729 4,799 Accrued compensation 808 9,735 Accrued clinical trial expenses (958) 2,726 Other accrued expenses 4,971 2,386 Liability related to refundable upfront payment - 12,500 Deferred revenue 15,477 (12,665) Other liabilities 1,046 (5,793) ----- ------ Net cash used in operating activities (13) (64,613) Cash flows from investing activities: Purchases of investments (314,439) (142,972) Maturities of investments 261,112 201,449 Sales of investments 8,823 4,969 Purchases of property, plant and equipment (7,283) (3,741) ------ ------ Net cash (used in) provided by investing activities (51,787) 59,705 Cash flows from financing activities: Payment of capital lease obligations (2,159) (5,376) Proceeds from shares issued under equity compensation plans 32,275 18,041 ------ ------ Net cash provided by financing activities 30,116 12,665 Effect of exchange rates on cash and cash equivalents 11 (32) Net (decrease) increase in cash and cash equivalents (21,673) 7,725 Cash and cash equivalents at beginning of period 59,640 55,570 Cash and cash equivalents at end of period $37,967 $63,295 Supplemental disclosure of cash flow information: Cash paid for interest $14,989 $15,513 

View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-reports-financial-results-for-the-third-quarter-of-2017-300551330.html

SOURCE Nektar Therapeutics